BMY Oct 2024 55.000 put
| Previous Close | 10.60 |
| Open | 10.60 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 55.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 10.60 - 10.60 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Business WireBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
PRINCETON, N.J., May 16, 2024--Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
- Reuters
CORRECTED-UPDATE 3-US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular lymphoma, that has returned or has not responded to prior treatments. The Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat follicular lymphoma patients who have received two or more prior lines of therapy. The approval provides an option with potential for lasting remission in a one-time infusion and a safety profile that allows for administration and monitoring in an increasing number of certified treatment centers in the U.S., said Bryan Campbell, Bristol Myers' head of commercial cell therapy in a statement.
ZacksBristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
